All GLP-1 receptor agonists and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
It works by enhancing insulin secretion, reducing glucagon levels, and slowing gastric emptying, which contributes to appetite suppression and weight reduction
Food cravings may return for the first time in months
Griffith, D.A., Edmonds, D.J., Fortin, J.P., Kalgutkar, A.S., Kuzmiski, J.B., Loria, P.M., Saxena, A.R., Bagley, S.W., Buckeridge, C., Curto, J.M., Derksen, D.R., Dias, J.M., Griffor, M.C., Han, S., Jackson, V.M., Landis, M.S., Lettiere, D., Limberakis, C., Liu, Y., Mathiowetz, A.M., Patel, J.C., Piotrowski, D.W., Price, D.A., Ruggeri, R.B., Tess, D.A
Liver findings included lower liver weight, reduced triglyceride content and less severe histological features of steatosis and inflammatory-cell infiltration in treated mice
GLP-1 inhibitors, such as Ozempic and Wegovy, are a class of medications originally developed to manage Type 2 diabetes but have now shown significant benefits in aiding weight loss